Pembrolizumab versus Ipilimumab in Advanced Melanoma
- PMID: 25891173
- DOI: 10.1056/NEJMoa1503093
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Abstract
Background: The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma.
Methods: In this randomized, controlled, phase 3 study, we assigned 834 patients with advanced melanoma in a 1:1:1 ratio to receive pembrolizumab (at a dose of 10 mg per kilogram of body weight) every 2 weeks or every 3 weeks or four doses of ipilimumab (at 3 mg per kilogram) every 3 weeks. Primary end points were progression-free and overall survival.
Results: The estimated 6-month progression-free-survival rates were 47.3% for pembrolizumab every 2 weeks, 46.4% for pembrolizumab every 3 weeks, and 26.5% for ipilimumab (hazard ratio for disease progression, 0.58; P<0.001 for both pembrolizumab regimens versus ipilimumab; 95% confidence intervals [CIs], 0.46 to 0.72 and 0.47 to 0.72, respectively). Estimated 12-month survival rates were 74.1%, 68.4%, and 58.2%, respectively (hazard ratio for death for pembrolizumab every 2 weeks, 0.63; 95% CI, 0.47 to 0.83; P=0.0005; hazard ratio for pembrolizumab every 3 weeks, 0.69; 95% CI, 0.52 to 0.90; P=0.0036). The response rate was improved with pembrolizumab administered every 2 weeks (33.7%) and every 3 weeks (32.9%), as compared with ipilimumab (11.9%) (P<0.001 for both comparisons). Responses were ongoing in 89.4%, 96.7%, and 87.9% of patients, respectively, after a median follow-up of 7.9 months. Efficacy was similar in the two pembrolizumab groups. Rates of treatment-related adverse events of grade 3 to 5 severity were lower in the pembrolizumab groups (13.3% and 10.1%) than in the ipilimumab group (19.9%).
Conclusions: The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma. (Funded by Merck Sharp & Dohme; KEYNOTE-006 ClinicalTrials.gov number, NCT01866319.).
Comment in
-
Immunotherapy: pembrolizumab-is the writing on the wall for cancer?Nat Rev Clin Oncol. 2015 Jul;12(7):371. doi: 10.1038/nrclinonc.2015.85. Epub 2015 May 12. Nat Rev Clin Oncol. 2015. PMID: 25963092 No abstract available.
Similar articles
-
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.JAMA. 2016 Apr 19;315(15):1600-9. doi: 10.1001/jama.2016.4059. JAMA. 2016. PMID: 27092830 Clinical Trial.
-
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).Lancet. 2017 Oct 21;390(10105):1853-1862. doi: 10.1016/S0140-6736(17)31601-X. Epub 2017 Aug 16. Lancet. 2017. PMID: 28822576 Clinical Trial.
-
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.Lancet. 2014 Sep 20;384(9948):1109-17. doi: 10.1016/S0140-6736(14)60958-2. Epub 2014 Jul 15. Lancet. 2014. PMID: 25034862 Clinical Trial.
-
Safety of pembrolizumab for the treatment of melanoma.Expert Opin Drug Saf. 2015 Jun;14(6):957-64. doi: 10.1517/14740338.2015.1021774. Epub 2015 Apr 30. Expert Opin Drug Saf. 2015. PMID: 25927979 Review.
-
Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.Medicine (Baltimore). 2017 Jun;96(26):e7325. doi: 10.1097/MD.0000000000007325. Medicine (Baltimore). 2017. PMID: 28658143 Free PMC article. Review.
Cited by
-
Expression of c-erb-B2 oncoprotein as a neoantigen strategy to repurpose anti-neu antibody therapy in a model of melanoma.Sci Rep. 2024 Oct 19;14(1):24545. doi: 10.1038/s41598-024-76209-z. Sci Rep. 2024. PMID: 39427012 Free PMC article.
-
Genetic Factors Associated with Clinical Response in Melanoma Patients Treated with Talimogene Laherparapvec: A Single-Institution Retrospective Analysis.Ann Surg Oncol. 2024 Oct 18. doi: 10.1245/s10434-024-16346-x. Online ahead of print. Ann Surg Oncol. 2024. PMID: 39422848
-
The many faces of autoimmune-mediated melanocyte destruction in melanoma.Front Immunol. 2024 Oct 3;15:1417273. doi: 10.3389/fimmu.2024.1417273. eCollection 2024. Front Immunol. 2024. PMID: 39421737 Free PMC article. Review.
-
Effectiveness of immune checkpoint inhibitors and other treatment modalities in patients with advanced mucosal melanomas: a systematic review and individual patient data meta-analysis.EClinicalMedicine. 2024 Oct 4;77:102870. doi: 10.1016/j.eclinm.2024.102870. eCollection 2024 Nov. EClinicalMedicine. 2024. PMID: 39416390 Free PMC article.
-
Increased myositis and possible myocarditis in melanoma patients treated with immune checkpoint inhibitors in the COVID-19 era.Cancer Immunol Immunother. 2024 Oct 5;73(12):259. doi: 10.1007/s00262-024-03803-5. Cancer Immunol Immunother. 2024. PMID: 39369180 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical